Bank of New York Mellon’s Utah Medical Products UTMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.36M Buy
34,263
+2,181
+7% +$145K ﹤0.01% 2851
2026
Q1
$1.99M Sell
32,082
-3,457
-10% -$218K ﹤0.01% 2817
2025
Q4
$1.99M Sell
35,539
-9,989
-22% -$579K ﹤0.01% 2836
2025
Q3
$2.87M Sell
45,528
-3,608
-7% -$213K ﹤0.01% 2624
2025
Q2
$2.8M Buy
49,136
+524
+1% +$28.5K ﹤0.01% 2583
2025
Q1
$2.72M Buy
48,612
+1,277
+3% +$76.5K ﹤0.01% 2535
2024
Q4
$2.91M Sell
47,335
-105
-0.2% -$6.79K ﹤0.01% 2582
2024
Q3
$3.17M Sell
47,440
-2,164
-4% -$147K ﹤0.01% 2539
2024
Q2
$3.31M Buy
49,604
+1,391
+3% +$94.7K ﹤0.01% 2536
2024
Q1
$3.43M Buy
48,213
+11,710
+32% +$878K ﹤0.01% 2499
2023
Q4
$3.07M Buy
36,503
+5,104
+16% +$423K ﹤0.01% 2608
2023
Q3
$2.7M Buy
31,399
+208
+0.7% +$19.2K ﹤0.01% 2642
2023
Q2
$2.91M Buy
31,191
+31
+0.1% +$2.92K ﹤0.01% 2627
2023
Q1
$2.95M Sell
31,160
-1,108
-3% -$102K ﹤0.01% 2582
2022
Q4
$3.24M Buy
32,268
+12,944
+67% +$1.18M ﹤0.01% 2583
2022
Q3
$1.65M Buy
19,324
+1,250
+7% +$110K ﹤0.01% 2952
2022
Q2
$1.55M Sell
18,074
-1,874
-9% -$160K ﹤0.01% 2976
2022
Q1
$1.79M Buy
19,948
+389
+2% +$35.8K ﹤0.01% 2996
2021
Q4
$1.96M Sell
19,559
-7,840
-29% -$800K ﹤0.01% 3010
2021
Q3
$2.54M Buy
27,399
+666
+2% +$58.8K ﹤0.01% 2850
2021
Q2
$2.27M Buy
26,733
+1,168
+5% +$101K ﹤0.01% 2904
2021
Q1
$2.21M Buy
25,565
+227
+0.9% +$20K ﹤0.01% 2873
2020
Q4
$2.13M Buy
25,338
+3,431
+16% +$292K ﹤0.01% 2811
2020
Q3
$1.75M Sell
21,907
-1,050
-5% -$87.1K ﹤0.01% 2750
2020
Q2
$2.03M Buy
22,957
+763
+3% +$68.5K ﹤0.01% 2662
2020
Q1
$2.09M Sell
22,194
-42
-0.2% -$3.9K ﹤0.01% 2521
2019
Q4
$2.4M Sell
22,236
-1,174
-5% -$119K ﹤0.01% 2706
2019
Q3
$2.24M Buy
23,410
+235
+1% +$21.8K ﹤0.01% 2687
2019
Q2
$2.22M Sell
23,175
-131
-0.6% -$11K ﹤0.01% 2743
2019
Q1
$2.06M Buy
23,306
+855
+4% +$75.2K ﹤0.01% 2761
2018
Q4
$1.87M Sell
22,451
-3,224
-13% -$284K ﹤0.01% 2757
2018
Q3
$2.42M Buy
25,675
+605
+2% +$57.8K ﹤0.01% 2742
2018
Q2
$2.76M Buy
25,070
+660
+3% +$68.9K ﹤0.01% 2675
2018
Q1
$2.41M Buy
24,410
+623
+3% +$55.6K ﹤0.01% 2709
2017
Q4
$1.94M Sell
23,787
-4,521
-16% -$353K ﹤0.01% 2859
2017
Q3
$2.08M Buy
28,308
+1,236
+5% +$88.9K ﹤0.01% 2814
2017
Q2
$1.96M Sell
27,072
-2,420
-8% -$159K ﹤0.01% 2864
2017
Q1
$1.84M Buy
29,492
+815
+3% +$51.3K ﹤0.01% 2902
2016
Q4
$2.09M Buy
28,677
+6,717
+31% +$437K ﹤0.01% 2827
2016
Q3
$1.31M Buy
21,960
+411
+2% +$26.1K ﹤0.01% 3027
2016
Q2
$1.36M Buy
21,549
+523
+2% +$33.7K ﹤0.01% 2946
2016
Q1
$1.31M Buy
21,026
+513
+3% +$30.3K ﹤0.01% 2899
2015
Q4
$1.2M Sell
20,513
-3,569
-15% -$202K ﹤0.01% 3043
2015
Q3
$1.3M Sell
24,082
-1,639
-6% -$89.4K ﹤0.01% 3019
2015
Q2
$1.53M Buy
25,721
+1,243
+5% +$70K ﹤0.01% 3083
2015
Q1
$1.47M Buy
24,478
+413
+2% +$24.3K ﹤0.01% 3073
2014
Q4
$1.45M Sell
24,065
-1,509
-6% -$83.6K ﹤0.01% 3068
2014
Q3
$1.25M Sell
25,574
-438
-2% -$22.2K ﹤0.01% 3167
2014
Q2
$1.34M Buy
26,012
+504
+2% +$25.9K ﹤0.01% 3146
2014
Q1
$1.48M Buy
25,508
+506
+2% +$27.6K ﹤0.01% 3079
2013
Q4
$1.43M Buy
25,002
+1,256
+5% +$68.9K ﹤0.01% 3090
2013
Q3
$1.41M Buy
23,746
+2,611
+12% +$143K ﹤0.01% 3056
2013
Q2
$1.15M Buy
+21,135
New +$995K ﹤0.01% 3117

Other funds holding UTMD

Bank of New York Mellon's UTMD Position: Q2 2026 in Review

Bank of New York Mellon increased its Utah Medical Products (UTMD) stake by 6.8% in Q2 2026, buying an estimated $145K and bringing the position to 34,263 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

Bank of New York Mellon first reported a position in UTMD in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.43M in Q1 2024. 56 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Bank of New York Mellon held 34,263 shares of Utah Medical Products worth $2.36M as of Q2 2026.
  • Bank of New York Mellon bought 2,181 Utah Medical Products shares in Q2 2026, an estimated $145K.
  • Utah Medical Products made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2851 holding.
  • Bank of New York Mellon first reported a position in Utah Medical Products in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Utah Medical Products position peaked at $3.43M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.